The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study
复制标题
DOI：
10.1016/j.ygyno.2007.04.032
复制
发表时间：
2007-07-01
影响因子：
4.7
通讯作者：
Rodgers, William H.
中科院分区：
文献类型：
--
作者：
McMeekin, D. Scott;Filiaci, Virginia L.;Rodgers, William H.
目标。目的探讨晚期或复发子宫内膜癌患者参加妇科肿瘤组化疗试验的组织学与预后的关系。使用各种分析方法评估年龄、种族、运动状态、组织学类型（浆液=S；透明细胞=CC；子宫内膜样细胞=E）、疾病分期和既往放疗，以评估缓解的可能性，并确定无病生存期（PFS）和总生存期（OS）进展的独立预测因素。在4项随机临床试验中，1203例患者采用单药或联合化疗方案，包括阿霉素(A)（12%）、阿霉素/顺铂（AP）（63%）、阿霉素/紫杉醇（AT）（13%）和紫杉醇/阿霉素/顺铂（TAP）（11%）。疾病分期为ⅲ期7.8%，ⅳ期22.8%，复发69.4%。组织学分布：S型占18%，CC型占3.7%，混合型占8.5%，E型占51.7%，其他型占18.1%。晚期（III-IV） S/CC患者（相对于复发性疾病）与E患者相比，更多的S/CC患者入组试验(45% vs. 24%,p
Objectives. To explore associations between histology and outcome in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials.Methods. Age, race, performance status, histologic type (serous=S; clear cell=CC; endometrioid=E), disease stage, and prior radiation were evaluated using various analytic methods to evaluate the probability of response and identify independent predictors of progress i o n-firee survival (PFS) and overall survival (OS).Results. Single agent or combination chemotherapy regimens including doxorubicin (A) (12%), doxorubicin/cisplatin (AP) (63%), doxorubicin/paclitaxel (AT) (13%), and paclitaxel/doxorubicin/cisplatin (TAP) (11%) were used among 1203 patients treated on 4 randomized clinical trials. Breakdown of disease stage was 7.8% stage III, 22.8% stage IV, and 69.4% recurrent disease. Histologic distribution was 18% S, 3.7% CC, 8.5% mixed, 51.7% E and 18.1% other. More S/CC patients enrolled on trials with advanced stage (III-IV) disease (as opposed to recurrent disease) compared to E patients (45% vs. 24%,p